Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib
 combined with docetaxel versus docetaxel, administered as first-line treatment, in patients
 with unresectable locally recurrent or metastatic breast cancer.
Inclusion Criteria:

 -  Breast cancer with evidence of unresectable locally recurrent, or metastatic disease

 -  Her-2 negative tumors

 Exclusion Criteria:

 -  Patients for whom docetaxel is contraindicated

 -  Clinical presentation of inflammatory carcinoma with no other measurable disease